Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer

Cancer/Radiotherapie

Volumn 13, Issue 4, 2009, Pages 298-304

  Belliere A ^a   Girard, N ^a   Chapet, O ^a   Khodri, M ^a   Kubas, A ^a   Souquet, P J ^a   Mornex, F ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Conformal radiotherapy; Dose escalation; Dose volume histogram; Non small cell lung cancer; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CARDIOTOXICITY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HISTOGRAM; HUMAN; IRRADIATION; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; HEART DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; REGRESSION ANALYSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 67649607503     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2009.04.004     Document Type: Article

References (27)

1. Belderbos J.S., Heemsbergen W.D., De Jaeger K., Baas P., and Lebesque J.V. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 126-134
2. Bradley J., Graham M.V., Winter K., Purdy J.A., Komaki R., Roa W.H., et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
3. Chapet O., Khodri M., Jalade P., N'guyen D., Flandin I., D'hombres A., et al. Potential benefits of using non-coplanar field and intensity-modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. Radiother Oncol 80 (2006) 333-340
4. Gayed I.W., Liu H.H., Yusuf S.W., Komaki R., Wei X., Wang X., et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 47 (2006) 1756-1762
5. Girard N., and Mornex F. Chemoradiation for locally advanced non-small-cell lung cancer. Cancer Radiother 11 (2007) 67-76
6. Hayman J.A., Martel M.K., Ten Haken R.K., Normolle D.P., Todd III R.F., Littles J.F., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 19 (2001) 127-136
7. Heidenreich P.A., Hancock S.L., Vagelos R.H., Lee B.K., and Schnittger I. Diastolic dysfunction after mediastinal irradiation. Am Heart J 150 (2005) 977-982
8. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
9. Karnofsky D.A., and Buchenal J.H. The clinical evaluation of chemotherapeutic agents. In: MacLeod C.M. (Ed). Evaluation of chemotherapeutic agents. (1949), Columbia University Press, New York 191-205
10. Kong F.M., Hayman J.A., Griffith K.A., Kalemkerian G.P., Arenberg D., Lyons S., et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65 (2006) 1075-1086
11. Marks L.B., Garst J., Socinski M.A., Sibley G., Blackstock A.W., Herndon J.E., et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina conformal therapy consortium. J Clin Oncol 22 (2004) 4329-4340
12. Marks L.B., Yu X., Prosnitz R.G., Zhou S.M., Hardenbergh P.H., Blazing M., et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63 (2005) 214-223
13. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 62 (2005) 1021-1032
14. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
15. Pavy J.J., Denekamp J., Letschert J., Littbrand B., Mornex F., Bernier J., et al. Late effects toxicity scoring: The SOMA-LENT scale. Int J Radiat Oncol Biol Phys 31 (1995) 1043-1047
16. Perez C.A., Bauer M., Edelstein S., Gillespie B.W., and Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradition. Int J Radiat Oncol Biol Phys 12 (1985) 539-547
17. Rosenman J.G., Halle J.S., Socinski M.A., Deschesne K., Moore D.T., Johnson H., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356
18. Socinski M.A., Blackstock A.W., Bogart J.A., Wang X., Munley M., Rosenman J., et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26 (2008) 2457-2463
19. Socinski M.A., Morris D.E., Halle J.S., Moore D.T., Hensing T.A., Limentani S.A., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
20. Stinchcombe T.E., Morris D.E., Lee C.B., Moore D.T., Hayes D.N., Halle J.S., et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high-dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small-cell lung cancer. J Thorac Oncol 3 (2008) 250-257
21. Sura S., Yorke E., Jackson A., and Rosenzweig K.E. High-dose radiotherapy for the treatment of inoperable non-small-cell lung cancer. Cancer J 13 (2007) 238-242
22. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
23. Travis W.D., Brambilla E., Muller-Hermelink H.K., and Harris N.L. Pathology and genetics of tumors of the lung, pleura, thymus, and heart. World Health Organization Classification of Tumours (2004), IARC Press, Lyon
24. Underberg R.W., van Sörnsen de Koste J.R., Lagerwaard F.J., Vincent A., Slotman B.J., and Senan S. A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. Radiat Oncol 1 (2006) 8
25. Urbanic J.J., Turrisi III A.T., Sharma A.K., Silvestri G.A., Williams T.E., Vanek K.N., et al. Conformal high-dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small-cell lung cancer: a retrospective analysis. J Thorac Oncol 1 (2006) 112-119
26. World Health Organisation. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization Offset Publication no. 48; 1979.
27. Wu K.L., Jiang G.L., Liao Y., Qian H., Wang L.J., Fu X.L., et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 57 (2003) 1336-1344